Lisdexamfetamine (Vyvanse) prior authorization at Highmark
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Highmark requires prior-authorization documentation for Lisdexamfetamine (Vyvanse): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return in 30 days; if denied, prescribers and members have 180 days to appeal.
The PA criteria you'll need to meet
Highmark reviews Lisdexamfetamine (Vyvanse) prior authorizations against its medical policy . Highmark-specific context: Operates BCBS in PA (western), WV, DE, NY (western). Owns Allegheny Health Network.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in this class
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Highmark's medical policy URL referenced in the cover letter
Highmark's common denial patterns
Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:
- Prior auth on biologics
- PA on advanced imaging
- OON balance bills
Lisdexamfetamine (Vyvanse)-specific denial patterns and context
Across payers (not just Highmark), Lisdexamfetamine (Vyvanse)draws a distinct set of denial reasons rooted in the drug's label, REMS, and competitive landscape:
- Step therapy requiring amphetamine first
- Non-formulary
- Quantity limit
Brand: Vyvanse. Generic available since 2023.
Manufacturer patient-assistance program: Takeda Help at Hand — relevant when a Highmark denial sticks and the patient needs bridge access while appealing.
How Highmark approaches Stimulants for ADHD PAs
Highmark's Stimulants for ADHD reviewer typically requires DSM-5 diagnosis documentation, prior-formulation trial when stepping to ER, and quantity within FDA-labeled maximum before approving Lisdexamfetamine. Pharmacy-benefit review for Lisdexamfetamine at Highmark is routed through Express Scripts. The 30-day standard review window starts when the prior-authorization request is received with all required documentation — incomplete packets pause the clock and add 5-10 days to time-to-approval, after which the 180-day internal-appeal window begins from the denial date. Highmark's controlled-substance overrides require prescriber attestation of DSM-5 ADHD diagnosis and a quantity rationale within the FDA-labeled daily maximum. Highmark is domiciled in PA, so unresolved appeals escalate to the PA insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead). Operates BCBS in PA (western), WV, DE, NY (western).
If the PA is denied
Highmark gives prescribers and members 180 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://www.highmark.com/provider) with the same packet plus a peer-reviewed citation supporting Lisdexamfetamine (Vyvanse)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Highmark denial on DenialHelp.
Contact Highmark
- Provider portal: https://www.highmark.com/provider
Frequently asked questions
What documentation does Highmark need for Lisdexamfetamine (Vyvanse) prior auth?
Highmark's typical PA packet for Lisdexamfetamine (Vyvanse): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis.
What's the turnaround time at Highmark?
Standard Lisdexamfetamine (Vyvanse) PA decisions at Highmark: 30 days. Urgent / expedited (member's life or function at risk): 72 hours under 45 CFR §147.136.
What does Highmark most often reject Lisdexamfetamine (Vyvanse) for?
Across Highmark's book the common rejection patterns include: Prior auth on biologics; PA on advanced imaging; OON balance bills. For Lisdexamfetamine (Vyvanse) specifically, expect step-therapy challenges and indication-restriction reviews when the use is at the edge of the FDA label or off-label.
Why does Highmark impose quantity limits on Lisdexamfetamine?
Controlled-substance quantity limits at Highmark typically track DEA Schedule II daily maximum dispensing rules and the FDA-labeled maximum daily dose for the formulation. Appeal a quantity limit by attaching prescriber attestation of the calculated daily dose, the formulation rationale (IR vs ER), and the DSM-5 diagnosis documentation. Federal law does not prohibit ADHD stimulant quantity limits — these are appealed on medical-necessity grounds, not parity grounds. Pharmacy-benefit handling is routed through Express Scripts. External-review escalation for Highmark fully-insured policies sits with the PA insurance department.
How do I prep for a peer-to-peer with Highmark on Lisdexamfetamine (Vyvanse)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the Lisdexamfetamine (Vyvanse) PA packet
Open ApprovalHelp — generate a Lisdexamfetamine (Vyvanse) prior-auth packet tailored to Highmark's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com